On January 7, INKON Life (300143) stated during an institutional investigation that the company is actively exploring AI + clinical innovation applications to empower diagnostic and therapeutic services. Currently, AI devices and systems have been gradually applied in the hospitals under the company, covering eight major scenarios: 3D visualization, imaging diagnosis, case generation, radiotherapy, intelligent follow-up, intelligent guidance, intelligent decision support, and intrinsic quality control, helping to enhance the hospital's diagnostic and therapeutic capabilities, experience level, and operational efficiency; in terms of diagnostic and therapeutic capabilities, the lung nodule detection rate has increased by 32% through AI + dual physician image review; in terms of experience level, 3D reconstruction makes treatment visualization possible, aiding communication between doctors and patients and simulating surgeries. In the future, INKON Life will continue to explore innovative applications of AI technology in clinical and medical device fields, continuously increasing investment in the healthcare sector and developing core competitiveness, while accelerating the layout and development of the entire industry chain for tumor prevention/diagnosis/treatment/recovery.